Olema oncology announces new preclinical combination data to be presented at the 2024 eortc-nci-aacr symposium on molecular targets and cancer therapeutics

Poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and op-3136, olema's kat6 inhibitor, in combination with palazestrant and other targeted agents poster presentations include new preclinical data demonstrating activity for palazestrant in combination with capivasertib and everolimus, and op-3136, olema's kat6 inhibitor, in combination with palazestrant and other targeted agents
NCI Ratings Summary
NCI Quant Ranking